ZUG, Switzerland — January 5, 2026 — Leads & Copy — CRISPR Therapeutics (Nasdaq: CRSP) announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 8:15 a.m. PT in San Francisco.
The presentation will be available via live webcast on the “Events & Presentations” page in the Investors section of the company’s website.
A replay of the webcast will be archived on the company’s website for 14 days following the presentation.
CRISPR Therapeutics, founded over a decade ago, is focused on developing transformative medicines for serious diseases. The company has evolved from a research-stage organization into an industry leader, marking a milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune, and rare diseases. The company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a gene-editing platform designed to enable precise, efficient, and scalable gene correction.
To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts, and San Francisco, California.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
Source: CRISPR Therapeutics
